AI Summary
This article discusses how the FDA has approved the subcutaneous administration of ocrelizumab for multiple sclerosis (MS) based on the results of a phase 3 trial. The study found that the subcutaneous form was just as effective as the intravenous infusion. This approval offers a new option for patients with MS.
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
Medscape Medical News